APA (7th ed.) Citation

Dan Peng, Yongqing Cai, Geng Chen, Min Hou, Xiaofeng Luo, Zhuoma Dongzhi, . . . Yao Liu. (2023). Efficacy and safety of apatinib versus sorafenib/placebo in first-line treatment for intermediate and advanced primary liver cancer: A systematic review and meta-analysis. Frontiers Media S.A..

Chicago Style (17th ed.) Citation

Dan Peng, Yongqing Cai, Geng Chen, Min Hou, Xiaofeng Luo, Zhuoma Dongzhi, Hongjun Xie, and Yao Liu. Efficacy and Safety of Apatinib Versus Sorafenib/placebo in First-line Treatment for Intermediate and Advanced Primary Liver Cancer: A Systematic Review and Meta-analysis. Frontiers Media S.A., 2023.

MLA (9th ed.) Citation

Dan Peng, et al. Efficacy and Safety of Apatinib Versus Sorafenib/placebo in First-line Treatment for Intermediate and Advanced Primary Liver Cancer: A Systematic Review and Meta-analysis. Frontiers Media S.A., 2023.